Shimla Online

Epilepsy Pipeline Assessment – FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

 Breaking News
  • No posts were found

Epilepsy Pipeline Assessment – FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

September 15
08:54 2022
Epilepsy Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

“DelveInsight’s Epilepsy Pipeline Insight 2022 report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in the Epilepsy pipeline landscape”

 

DelveInsight’s ‘Epilepsy Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline epilepsy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the epilepsy pipeline domain.

 

For epilepsy emerging drugs, the Epilepsy pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

Key highlights from the Epilepsy Pipeline Report

  • DelveInsight’s Epilepsy Pipeline analysis depicts the space with 70+ active players working to develop 70+ pipeline therapies.
  • Out of the emerging epilepsy therapies, XEN1101 is in the late stage of development, whereas Lu AG06466 is in the early stage of development.
  • Epilepsy Pipeline Companies such as Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, CombiGene, and others are evaluating novel epilepsy treatment drugs candidate to improve the treatment landscape.
  • Key epilepsy pipeline therapies in various stages of development include Perampanel, Alprazolam, XEN1101, GWP42006, EQU-001, TAK-935, Lu AG06466, OPC-214870, CG 01, and others.

 

Get to know more in-depth information about the Epilepsy Pipeline Report, click here: Epilepsy Pipeline Insight

 

Epilepsy Overview

Epilepsy is a chronic disorder that causes unprovoked, recurrent seizures. A seizure is a sudden rush of electrical activity in the brain. There are two main types of seizures. Generalized seizures affect the whole brain. Focal, or partial seizures, affect just one part of the brain. A mild seizure may be difficult to recognize. It can last a few seconds during which you lack awareness. Stronger seizures can cause spasms and uncontrollable muscle twitches, and can last a few seconds to several minutes. During a stronger seizure, some people become confused or lose consciousness. Afterward you may have no memory of it happening. Epilepsy is a fairly common neurological disorder that affects people around the world. In the United States, it affects about 3 million people.

 

Epilepsy Emerging Drugs

XEN1101: Xenon Pharmaceuticals

Xenon 1101, a differentiated KV7 potassium channel opener, for treatment of epilepsy. The Kv7 potassium channel mechanism has been clinically validated with ezogabine, an earlier generation Kv7 opener that was approved by the FDA as an adjunctive treatment for adults with focal seizures with or without secondary generalization.

Lu AG06466: Abide therapeutics

Lu AG06466 (formerly ABX 1431) is an oral, small molecule, being developed by Abide Therapeutics (now Lundbeck A/S), for the treatment of neuropathic pain, Epilepsy. Currently, the drug is in Phase I stage of development for the treatment of Epilepsy.

TAK-935: Takeda Pharmaceuticals

Soticlestat is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. 24HC is a positive allosteric modulator of the NMDA receptor and modulates glutamatergic signaling associated with epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel and that increased expression of CH24H can disrupt the reuptake of glutamate by astrocytes, resulting in epileptogenesis and neurotoxicity. Inhibition of CH24H by soticlestat reduces the neuronal levels of 24HC and may improve excitatory/inhibitory balance of NMDA channel activity.

 

For further information about Epilepsy treatment and pipeline therapies, visit Epilepsy Pipeline Therapies

 

 

Epilepsy Pipeline Therapeutics Assessment

By Product Type

  • Monotherapy
  • Combination Therapy

By Stage

  • Discovery
  • Pre-Clinical
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Route of Administration

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

By Molecule Type

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Epilepsy Pipeline Therapeutics Analysis

There are approx. 70+ key companies which are developing therapies for Epilepsy. The companies which have their Epilepsy drug candidates in the most advanced stage, i.e. phase II include, Xenon Pharmaceuticals.

 

Epilepsy Pipeline Phases

DelveInsight’s Report covers around 70+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

For further information about Epilepsy treatment and pipeline therapies, visit @ Epilepsy Pipeline Assessment

 

Epilepsy Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.
  • Epilepsy key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Epilepsy Drugs are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.
  • The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. 

 

Scope of the Epilepsy Pipeline Report

  • Coverage: Global
  • Epilepsy Companies: Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals (NASDAQ: XENE), GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, and others
  • Epilepsy Pipeline Therapies: Perampanel, Alprazolam, XEN1101, GWP42006, EQU-001, TAK-935, Lu AG06466, OPC-214870, and others
  • Epilepsy Preclinical and Discovery Stage Products
  • Epilepsy Inactive Products
  • Epilepsy Market Drivers and Barriers
  • Epilepsy Future Perspectives and Conclusion
  • Epilepsy Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Epilepsy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Epilepsy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug name: Company name
  9. Last Stage Products (Phase III)
  10. Drug name: Company name
  11. Mid Stage Products (Phase II)
  12. XEN1101:Xenon Pharmaceuticals
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company Name
  15. Inactive Products
  16. Epilepsy Key Companies
  17. Epilepsy Key Products
  18. Epilepsy – Unmet Needs
  19. Epilepsy – Market Drivers and Barriers
  20. Epilepsy – Future Perspectives and Conclusion
  21. Epilepsy Analyst Views
  22. Epilepsy Key Companies
  23. Appendix

 

Got Queries? Reach out for more information @ Epilepsy Clinical Trials

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles